|
|
Speaker Conflict of Interest Declarations |
Consequences of Hyperphosphatemia:
Are We Accepting the Unacceptable?
University of Minnesota
CME Internet Course
Conflict of Interest,
Trade Name, and
Nonindicated Use Information
Use of the Renagel® Capsules Trade Name
Generally, generic names are used in CME activities in order to avoid real or apparent product promotion. In this symposium, the name Renagel® Capsules will appear in some slides and be used in at least one presentation. The reason for this is the excessively general and cumbersome generic term poly(allylamine hydrochloride)/sevelamer hydrochloride. For this reason, Renagel® Capsules is the term actually used in most of the scientific literature in which this product is discussed. Using the trade name in this case is not meant to single out or in any way recommend one product over another.
Conflict of Interest Information
The University of Minnesota Office of Continuing Medical Education has a conflict of interest policy that requires course faculty to disclose whether or not they have financial interests or affiliations with organizations with a direct and substantial interest in the subject matter of their presentations. The following information was received from course faculty for "Consequences of Hyperphosphatemia: Are We Accepting the Unacceptable?" November 5, 1999, Miami, FL.
It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations. They simply are noted here to fully inform course participants.
Course Faculty
David Bushinsky, MD: Honorarium - Genzyme Therapeutics
Glenn Chertow, MD, MPH: Grants and Research Support from Geltex Pharmaceuticals
Eduardo Slatopolsky, MD: Grants/Research Support - Abbott Laboratories; Consultant - Genzyme Therapeutics, Abbott Laboratories, Merck and Compancy, Inc., Lilly Corporation, Pfizer Pharmaceuticals, Amgen; Honorarium - Genzyme Therapeutics.
Nonindicated Uses
One of the educational goals of continuing medical education is the free discussion of reasonable treatment options, which sometimes include nonindicated uses for some medications. This symposium may contain such discussions, when warranted by research results and clinical experience. Generally, speakers will indicate when the uses they are suggesting are off-label.
Go to CME Information
Go to Enrollment
Go to Posttest
Go to Evaluation